This review summarizes current recommendations for the use of antiplatelet agents, including aspirin, clopidogrel, and glycoprotein IIb/IIIa inhibitors, in the treatment of NSTEACS.
This review summarizes the current European Society of Cardiology guidelines and recommendations for antiplatelet therapy in patients with NSTEACS undergoing PCI.
Non-ST-segment elevation acute coronary syndrome (NSTEACS) is the leading cause of hospital admission for ischaemic heart disease. Despite major progress in diagnosis and treatment, NSTEACS remains to be associated with poor short-and long-term prognoses. For this reason, it appears reasonable to follow the guidelines of the European Society of Cardiology and recommend optimal and intensive pharmacotherapy including antiplatelet agents and invasive cardiac procedures, especially in NSTEACS patients at high risk of death and/or myocardial infarction. Aspirin, clopidogrel, and glycoprotein IIb/IIIa inhibitors are the most frequent antiplatelet agents used for the treatment of NSTEACS. This article summarizes current recommendations for use those agents in NSTEACS treatment.
Dudek et al. (Thu,) conducted a review in Non-ST-segment elevation acute coronary syndrome (NSTEACS). Antiplatelet agents (Aspirin, clopidogrel, glycoprotein IIb/IIIa inhibitors) was evaluated. This review summarizes current recommendations for the use of antiplatelet agents, including aspirin, clopidogrel, and glycoprotein IIb/IIIa inhibitors, in the treatment of NSTEACS.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: